

APPLICATION

PLEASE CHE	CK ALL THAT API	PLY					
	thorization on file author s for Benefit Verification		patient's identification a	and insu	ance inf	formation to Sanofi US, and their age	nts
Reimbursement Connection (BV) ☐ BV only (Complete sections 1-3) (No signatures required) ☐ BV and Patient Assistance (If no coverage is found, prescriber and patient signature required) (Complete sections 1-3, 5)			□ Patient Assistance Connection No cost medication program, prescriber and patient signature required (Complete sections 1-3, 5) SANOFI → Foundation for Poundation for SANOFI → Foundation for Poundation for Poundation for			☐ Resource Connection Additional patient resources, patient signature required (Complete sections 1-5)	
1. PATIENT INF	ORMATION						
First Name:		MI: Last N	ame:			Gender: M F	
	Ci		: State			Zip Code:	
						No Insurance? □	
Primary Insurance:			Secondary Insura				
Policy #:			Policy #:				
Policy Holder Name:			Policy Holder Na	me:			
Date of Birth:			Date of Birth:				
Insurance Phone #:			Insurance Phone	#:			
Group #:			Group #:				
2. TREATMENT	AND PRESCRIBI	NG INFORMATIO	V (see instructions	s on pa	ge 3 fo	or available products)	
	argine injection) 100 Ur	nits/mL and/or Apidra [®]	(insulin glargine [rDN	•		on), indicate vials or pens. All other	
Drug:	ICD/Dx:		Rx:	Qty	/:	Refills:	
Drug:	ICD/Dx:		Rx:	Qty	/:	Refills:	П
Drug:	ICD/Dx:		Rx:	Qty	<i>/</i> :	Refills:	
3. PRESCRIBE	R INFORMATION						
Prescriber Name:		Prescriber Typ	e:		State w	vhere Licensed:	
						DEA#:	
						State License #:	
•	·					utpatient	_
						Zip Code:	
•	-		hospital address aut	horized	by the p	rescriber and not to a 3rd party.	
Primary Contact Name:			Title/Role:				
Primary Phone #:	Pr	imary Fax #:	Prin	nary Em	ail:		
medically necessary that I have obtained insurance information that any information eligibility for participa services. I understar benefit from Sanofi coffice or hospital ad named patient only a from any payer, patie	for this patient and that from my patient all re n to Sanofi US and/or provided is for the sole ation in the patient assimat that I am under no or their agents or repredress. My signature cand will not be resold nent or other source for patients.	at I am authorized undi- quired written authorizante Sanofi Foundation The Sanofi Foundation use of the Program to stance program and to obligation to prescribe sentatives for prescribe ertifies that any preso or offered for sale, trac product received from	er State law to prescreation for the release on for North America overify my patient's in otherwise administed any Sanofi producting a Sanofi product. In products recede or barter and will nother Program.	ribe and of my pand the asurance reference the Said The factived from the factived from the factived from the reference the said the said the factived from the factived from the factived from the factived from the factive	dispens atient's ir agent's covera nofi Pati t I have ility add m this Furned for the second	e. I certify that the Sanofi product se the requested medication. I certiful personal identification, medical arts and representatives. I understange, to assess, if applicable, patient Connection program and related not received nor will I receive and ress noted above in Section 3 is not program will be used for the above or credit, nor will payment be sough	ify nd nd t's ed ny ny
	Prescriber Signature (requi	rea – no stamps)	Prir	nted Name	•	Date	

4. RESOURCE CONNECTION		
Does the patient wish to have the program contact them to help identify ☐ Yes (Patient signature required below) ☐ No If yes, please mark which resources the patient may be interested in if a ☐ Clinical Support Services ☐ Transportation ☐ Patient Advocat ☐ Health Supplies/Cosmetic Aids (wigs, scarves, etc.) ☐ Home Care S	available: cy Support	(groceries, food banks, etc.) Other:
Please indicate patient's primary language if other than English:		
5. PATIENT ASSISTANCE CONNECTION (certification and authorize	tation to disclose information)	
Total # of people in the household: $\Box 1$ $\Box 2$ $\Box 3$ $\Box 4$ $\Box 5$	☐ Other:Annual Househo	old Income: \$
Income Verification: Sanofi Patient Connection and its authorized additional demographic information as needed to access my credit estimate my income in conjunction with the eligibility determination Sanofi Patient Connection and its authorized third party agents research.	information and information derived from process. As a soft credit inquiry, this opt	n public and other sources to ion will not impact my credit score.
Patient Name (Please Print): I, connection with this application are complete and accurate. I agree Healthcare Provider if my income or insurance status changes duri information will be used by the Program sponsor, Sanofi US, its afficompany), The Sanofi Foundation for North America, and authoriz "Program Sponsor"), for purposes of determining my participation in well as my Doctor/Healthcare Provider, office/hospital staff, insurer contact me for follow-up on any adverse event I may report regardinformation about me including medical, financial and insurance required information includes release of information relating to treatment for results or diagnosis, if required. I understand that identifiable inform disclosed except to administer the Program, or as required by law. disclosed and is no longer protected by Federal privacy regulations this authorization. Refusal to sign will not affect my ability to obtain revoked, this authorization shall remain in effect throughout my parmay withdraw this authorization at any time by written notification to terminate my participation in this Program and will not affect inform responsibility to follow-up with my prescriber or the Program to make so I do not run out of medication. I understand that Sanofi US and without notice to modify or change eligibility criteria, or modify or distance of the program of the following persons the sanofi Patient Connection to speak with the following persons to the program of the following persons the sanofi Patient Connection to speak with the following persons to the program in the following persons to the following pe	ing the course of my participation in this filiated companies (i.e. Sanofi Pasteur U.Sed third party agents involved in administin, and administering, the Program, which (public/private) or others. I understand a fing a Sanofi product. I authorize and constructed and information as required for participation about me will be kept confidential at understand that information I authorize is. I agree that this authorization is voluntative treatment but I will not be able to participation in the Program, including subsetticipation in the Program, including subsettion already disclosed under this Authorite sure that my re-orders, as appropriate The Sanofi Foundation for North Americal scontinue this Program.	Program. I understand that my S. and Genzyme, a Sanofi tration of this Program, (collectively may include contacting me as a representative from Sanofi may sent to release of identifiable ticipation in the Program. My medical conditions, and HIV test and will not be further used or to be disclosed may be reary and that I may refuse to sign pate in this Program. Unless equent reapplication as required. I er withdrawal of authorization will rization. I understand that it is my are shipped in a timely manner a reserve the right at any time and
status of my application request.		
SIGN HERE Patient Signature	Relationship:Printed Name	Phone #:
APPLICATION CHECKLIST (application will be delayed	if all information is not received)	
HIPAA consent checked or provider signature included	Code Otata License Nov. 1	- Deteile
The following must be completed as needed: Dosage, Diagnosis		Details
Signatures of prescriber and patient (required for Patient AssistaSignature of patient (required for Resource Connection)	ince Connection)	
- Signature of patient (required for recodure confidential)		

PRODUCT SELECTION (please enter desired product in Section 2 for all services)

- Adacel[®] (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)
- Adlyxin[™] (lixisenatide) injection
- Apidra[®] (insulin glulisine [rDNA origin] injection)
- Clolar® (clofarabine) Injection
- Elitek[®] (rasburicase)*
- Imogam® Rabies-HT Immune Globulin, [Human] USP, Heat Treated
- Imovax® Rabies Vaccine [Human Diploid Cell]
- Jevtana® (cabazitaxel) Injection*
- Lantus® (insulin glargine injection) 100 Units/mL
- Leukine[®] (sargramostim)
- Lovenox[®] (enoxaparin sodium injection)*

- Menactra[®] Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine
- Menomune[®] (Meningococcal Polysaccharide Vaccines Groups A, C,Y and W-135 combined)
- Mozobil® (plerixafor injection)
- Multaq[®] (dronedarone) Tablets*
- Priftin® (rifapentine) Tablets
- SOLIQUATM 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL and 33 mcg/mL
- Tenivac[®] (tetanus and diphtheria toxoids adsorbed)
- Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)]
- Toujeo® (insulin glargine injection) 300 units/mL
- Zaltrap[®] (ziv-aflibercept)*

*Please see full U.S. prescribing information, including Black Box warning.

Full U.S. prescribing information for all Sanofi Patient Connection supported products can be accessed at www.visitspconline.com.

PATIENT ASSISTANCE CONNECTION ELIGIBILITY REQUIREMENTS

- An application must be submitted for each patient.
- Patient must be a U.S. citizen or resident and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S. (State License Number is required in Section 3).
- · Patient must have no insurance coverage or not have access to the prescribed product or treatment via their insurance.
- If a patient has Medicare Part D coverage they can be assessed for patient assistance eligibility by meeting these criteria:
 - Not be eligible for Low Income Subsidy (LIS)
 - Not have coverage for a generic equivalent product
 - Have an out-of-pocket (OOP) total drug spend of 5% of their annual income
- If a patient appears to be eligible for Medicaid they may be required to provide documentation of Medicaid denial before being assessed for patient assistance eligibility.
- Patient must meet the following financial criteria:
 - Annual household income of ≤250% of the current Federal Poverty Level* for all non-Oncology/non-Hematology products
 - Annual household income of ≤500% of the current Federal Poverty Level* for all Oncology and Hematology products
- If applying for Drug Replacement (Lovenox, Oncology and Hematology products only), a copy of the claim, denial, flow sheet(s) and drug dispensing log (with patient name, date of service, product NDC/Lot#, total dosage) must be submitted.
- For Vaccines, patient must be 19 years of age or older (except for IMOVAX RABIES and IMOGAM RABIES HT).

*To assess current Federal Poverty Level details, visit: http://aspe.hhs.gov.



ADDITIONAL INFORMATION

- · A representative from Sanofi may contact you for follow-up on any adverse event you may report regarding a Sanofi product.
- Sanofi Patient Connection is also pleased to provide you with access to the "SPC Education Center" by calling 855.977.2338 (855.9SPCEDU), Monday through Friday, 9:00am to 8:00pm ET. You can speak to a live counselor dedicated to:
- Providing information about local healthcare reform related resources
- Directing you to either the federal or state-run Health Insurance Marketplace

FORM SUBMISSION OPTIONS







Fax 1.888.847.1797



U.S. Mail

